October 17, 2022
RFA-CA-22-013 - PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24 Clinical Trial Not Allowed)
National Cancer Institute (NCI)
The purpose of this Notice is to correct the Table for Key Dates in RFA-CA-22-013, PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24 Clinical Trial Not Allowed).
The following section has been corrected:
Part 1. Overview Information, Key Dates
Currently reads:
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
November 01, 2022 |
Not Applicable |
Not Applicable |
March 2023 |
May 2023 |
July 2023 |
Corrected to read (in bold italics):
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
November 01, 2022 |
November 01, 2022 |
Not Applicable |
March 2023 |
May 2023 |
July 2023 |
All other aspects of RFA-CA-22-013 remain unchanged.
Scientific/Research Contact(s)
Jeffrey A. Moscow, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-6565
Email: jeffrey.moscow@nih.gov
Peer Review Contact(s)
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci.nih.gov
Financial/Grants Management Contact(s)
Shane Woodward
National Cancer Institute (NCI)
Telephone: 240-276-6303
Email: woodwars@mail.nih.gov
and Human Services (HHS)
